PLOD1 and polycystic ovary syndrome: In PCOS patients receiving follicular phase GnRH agonist protocols, however, endogenous LH generation is inhibited, and the body loses the potential mechanism of inhibiting ovarian overstimulation due to the downregulated pituitary function.